Inventor
ISAAC METHVIN
CA37 patents
⚠️ This page may combine multiple inventors who share the name “ISAAC METHVIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ASTRAZENECA AB
19 patentsUS7112595B2Sep 26, 2006
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ASTRAZENECA AB92 citations95
US7485722B2Feb 3, 2009
Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
ASTRAZENECA AB29 citations92
US7585881B2Sep 8, 2009
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ASTRAZENECA AB36 citations88
US7799792B2Sep 21, 2010
Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841
ASTRAZENECA AB11 citations83
US7960422B2Jun 14, 2011
Pharmaceutically active compounds containing tetrazolyl and triazolyl rings
ASTRAZENECA AB11 citations82
US7868008B2Jan 11, 2011
Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
ASTRAZENECA AB11 citations81
US7476684B2Jan 13, 2009
Compounds for the treatment of neurological, psychiatric or pain disorders
ASTRAZENECA AB11 citations79
US7456200B2Nov 25, 2008
Compounds
ASTRAZENECA AB9 citations79
US7807706B2Oct 5, 2010
Metabotropic glutamate-receptor-potentiating isoindolones
ASTRAZENECA AB6 citations71
US7772235B2Aug 10, 2010
mGluR5 modulators
ASTRAZENECA AB2 citations62
US8377940B2Feb 19, 2013
Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842
ASTRAZENECA AB4 citations61
US7968570B2Jun 28, 2011
Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
ASTRAZENECA AB6 citations60
US7678796B2Mar 16, 2010
MGluR5 modulators I
ASTRAZENECA AB3 citations55
US8377939B2Feb 19, 2013
Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842
ASTRAZENECA AB0 citations51
US7935703B2May 3, 2011
Piperazines and piperidines as Mglur5 potentiators
ASTRAZENECA AB1 citations51
US7790717B2Sep 7, 2010
Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
ASTRAZENECA AB0 citations51
US7576077B2Aug 18, 2009
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
ASTRAZENECA AB2 citations47
US7816354B2Oct 19, 2010
Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
ASTRAZENECA AB0 citations40
US7691892B2Apr 6, 2010
Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
ASTRAZENECA AB0 citations39
NPS ALLELIX CORP
5 patentsUS6426364B1Jul 30, 2002
Diaryl-enynes
NPS ALLELIX CORP14 citations89
US6897215B1May 24, 2005
Compounds having 5-HT6 receptor antagonist activity
NPS ALLELIX CORP11 citations74
US6380242B1Apr 30, 2002
N-alkylamino-indoles for the treatment of migraine
NPS ALLELIX CORP11 citations73
US6579987B2Jun 17, 2003
Diaryl-enynes
NPS ALLELIX CORP0 citations49
US6525085B2Feb 25, 2003
Diaryl-enynes
NPS ALLELIX CORP0 citations49
ONTARIO INSTITUTE FOR CANCER RES OICR
4 patentsUS11505539B2Nov 22, 2022
Deuterated compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders
ONTARIO INSTITUTE FOR CANCER RES OICR3 citations69
US11518764B2Dec 6, 2022
Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
ONTARIO INSTITUTE FOR CANCER RES OICR3 citations67
US11192880B2Dec 7, 2021
Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders
ONTARIO INSTITUTE FOR CANCER RES OICR0 citations58
US11242351B2Feb 8, 2022
Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
ONTARIO INSTITUTE FOR CANCER RES OICR0 citations47
PROPELLON THERAPEUTICS INC
3 patentsUS11174250B2Nov 16, 2021
Substituted carboxamides as inhibitors of WDR5 protein-protein binding
PROPELLON THERAPEUTICS INC3 citations67
US12264147B2Apr 1, 2025
Substituted carboxamides as inhibitors of WDR5 protein-protein binding
PROPELLON THERAPEUTICS INC0 citations55
US11319299B2May 3, 2022
Substituted carboxamides as inhibitors of WDR5 protein-protein binding
PROPELLON THERAPEUTICS INC1 citations55